Alphamab Oncology’s JSKN003 ADC: Promising Preliminary Data in Advanced Solid Tumors
Alphamab Oncology (HKG: 9966) has released preliminary data from a Phase I clinical study on...
Alphamab Oncology
Alphamab Oncology and 3D Medicines Gain FDA Approval for Envafolimab Phase III Trial
Partners Alphamab Oncology (HKG: 9966) and 3D Medicines (HKG: 1244) have announced that they have...
Alphamab Oncology Presents Promising Data for KN046 and KN026 at ESMO 2023
China-based Alphamab Oncology (HKG: 9966) has released data snapshots from clinical studies for two of...
Alphamab Oncology Enters Licensing Agreement with Grand Life Sciences for KN057 in Greater China
China-based Alphamab Oncology (HKG: 9966) has announced a licensing agreement with fellow Chinese firm Grand...
Ascletis Pharma’s ASC22 Combo Therapy Shows Promise in HIV Functional Cure Clinical Trial
China-based Ascletis Pharma Inc., (HKG: 1672) has announced that the Shanghai Public Health Clinical Center...
Chinese Pharma Companies Update Pipelines at ASCO 2023 Annual Meeting
A number of Chinese pharmaceutical companies have shared updates on their pipeline developments at the...
Alphamab Oncology and CSPC Pharma Get Green Light for KN026 Phase III Study in Breast Cancer
China-based Alphamab Oncology (HKG: 9966) and CSPC Pharmaceutical Group Ltd (HKG: 1093) have announced receiving...
Luye Pharma’s BA1102 Biosimilar to Xgeva Accepted for CDE Review
China-based Luye Pharma Group (HKG: 2186) has announced that a market approval filing for its...
Alphamab Oncology Partners with Stemirna for BsAb and mRNA Vaccine Development
China-based Alphamab Oncology (HKG: 9966) has announced a strategic partnership with Shanghai-based mRNA drug developer...
3D Medicines Gains FDA Approval for Phase II Study of Envafolimab in dMMR Tumors
China-based oncology specialist 3D Medicines (HKG: 1244) has announced receiving approval from the US FDA...
Tracon Pharmaceuticals Provides Positive Update on Envafolimab Phase II Trial
China-based Alphamab Oncology (HKG: 9966)’s US partner Tracon Pharmaceuticals (NASDAQ: TCON) has provided an early...
Alphamab Oncology Updates Clinical Studies for KN046 and KN026 at SABCS 2022
China-based Alphamab Oncology (HKG: 9966) updated the clinical studies for its KN046 and KN026 at...
Alphamab Oncology and CSPC Announce Positive Phase II Data for KN026 in HER2-Positive Gastric Cancer
China-based Alphamab Oncology (HKG: 9966) and CSPC Pharmaceutical Group Ltd (HKG: 1093) have announced the...
Alphamab Oncology Gains NMPA Approval for JSKN003 Clinical Trial
Alphamab Oncology (HKG: 9966) announced that it has received approval from the National Medical Products...
Alphamab Oncology’s KN019 Achieves Primary Endpoint in Phase II RA Study
Suzhou-based biotech Alphamab Oncology (HKG: 9966) has announced that its China-based Phase II KN019-201 study,...
Alphamab Oncology Doses First Patient in Phase I Study for JSKN003 in Australia
Alphamab Oncology (HKG: 9966) has announced that the first patient has been dosed in a...
Ascletis Completes Enrollment for HIV Functional Cure Study with PD-L1 Antibody ASC22
China-based Ascletis Pharma Inc. (HKG: 1672) announced that the clinical study of PD-L1 antibody ASC22...
Alphamab/3DMed’s Envafolimab Gains FDA Fast-Track Status for Sarcoma Treatment
Alphamab Oncology (HKG: 9966) and 3D Medicines’ envafolimab (KN035) has obtained fast-track status from the...
Alphamab Oncology Highlights KN046, KN026 Advances at ESMO 2022
China’s Alphamab Oncology (HKG: 9966) will present updated clinical data for its bispecific antibody candidates...
Alphamab Oncology Reports H1 2022 Revenue Growth Driven by Envafolimab Commercialization
China-based Alphamab Oncology (HKG: 9966) reported RMB 53.57 million (USD 7.7 million) in H1 2022...